Skip to main content
TipRanks
Go Ultimate75% OFF

Nureca Ltd. (NURECA) AI Stock Analysis

0 Followers
IN:NURECA

Nureca Ltd.

(NSE:NURECA)

Select Model
Rating:58Neutral
Price Target:INR 310.00â–²(4.36% Upside)
Action:reiterated
Date:09/29/26

The overall score of 58 reflects a company in the early stages of a financial turnaround, supported by a very strong balance sheet. The primary positive driver is the bullish technical momentum, indicating market confidence in the recovery. However, this is significantly offset by an extremely high valuation (P/E of 88.5) and the company's currently thin profitability and fragile cash flows, which present substantial risk if the growth trajectory falters.

Positive Factors
Conservative balance sheetVery low leverage gives Nureca financial flexibility and reduces the risk that interest obligations restrict operations or investment. This conservative funding structure is especially valuable while earnings remain variable, allowing the company to pursue growth without relying heavily on additional debt.
Negative Factors
Thin profitability marginsThin net and operating margins leave limited room to absorb higher costs, execution mistakes, or changes in product demand. They also mean that modest pressure on revenue or expenses could materially reduce earnings, making durable profit expansion dependent on meaningful margin improvement.

Nureca Ltd. (NURECA) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%30%40%IN:NURECA+13.83%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 2.97B
Dividend Yield
―
Average Volume (3M)
858
Price to Earnings (P/E)
62.7
Beta (1Y)
0.82
Revenue Growth
33.66%
EPS Growth
17.10%
Country
India
Employees
154
Sector
General
Sector Strength
55
Industry
Medical - Devices

Nureca Ltd. Business Overview & Revenue Model

Company Description

Operating in India, Nureca Limited is a business-to-consumer (B2C) firm specializing in home healthcare and general wellness solutions. Their extensive product portfolio addresses various health needs, encompassing items for managing chronic conditio...

Nureca Ltd. Financial Statement Overview

Summary

Nureca is showing a recovery with two years of revenue growth and a return to profitability. However, net margins remain very thin at 1.4% and cash flow, while improved, is still fragile. The strong, debt-light balance sheet is a major positive, but overall financial health is tempered by low profitability and historically volatile cash generation.

Income Statement

48Neutral

Balance Sheet

82Very Positive

Cash Flow

42Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.74B1.47B1.10B919.28M1.11B2.56B
Gross Profit444.82M352.34M231.33M311.42M355.94M1.23B
EBITDA111.18M85.19M48.95M2.41M-79.04M632.04M
Net Income47.60M20.82M8.46M-17.94M-82.50M449.60M
Balance Sheet
Total Assets2.31B1.96B2.10B2.05B2.07B2.19B
Cash, Cash Equivalents and Short-Term Investments735.52M424.31M736.29M1.44B1.02B927.10M
Total Debt66.01M22.59M49.66M25.16M33.27M44.05M
Total Liabilities433.97M153.96M156.91M120.54M116.97M159.32M
Stockholders Equity1.88B1.81B1.94B1.93B1.95B2.03B
Cash Flow
Free Cash Flow017.45M-234.06M-37.98M98.31M-46.00M
Operating Cash Flow085.74M-190.83M-27.12M102.27M13.99M
Investing Cash Flow081.20M84.39M175.76M-164.56M-30.89M
Financing Cash Flow0-184.66M-1.69M-13.03M-15.07M-73.02M

Nureca Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price297.05

Price Trends

50DMA326.00Negative
100DMA309.86Negative
200DMA286.52Positive

Market Momentum

MACD-7.42Positive
RSI38.28Neutral
STOCH48.61Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Negative. The current price of 297.05 is below the 20-day moving average (MA) of 309.62, below the 50-day MA of 326.00, and above the 200-day MA of 286.52, indicating a neutral trend. The MACD of -7.42 indicates Positive momentum. The RSI at 38.28 is Neutral, neither overbought nor oversold. The STOCH value of 48.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NURECA.

Nureca Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:NURECA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:BLUEJETIN:BLUEJET71OutperformINR 96.53B31.91―0.23%-7.05%-21.25%
IN:PGHLIN:PGHL64NeutralINR 90.83B23.88―3.86%13.04%4.60%
IN:AMRUTANJANIN:AMRUTANJAN62NeutralINR 14.87B25.64―0.96%10.68%-1.04%
IN:NURECAIN:NURECA58NeutralINR 2.83B62.69――33.66%17.10%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ZOTAIN:ZOTA45NeutralINR 39.15B-38.48―0.08%68.95%-55.82%

* General Sector Average

Performance Comparison

-40%-20%0%20%IN:NURECAIN:AMRUTANJANIN:BLUEJETIN:PGHLIN:SANOFICONRIN:ZOTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:NURECA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:NURECANureca Ltd.297.0534.0512.95%
IN:AMRUTANJANAmrutanjan Health Care Limited508.75-187.17-26.90%
IN:BLUEJETBlue Jet Healthcare Limited510.00-57.96-10.21%
IN:PGHLProcter & Gamble Health Ltd.5472.05-189.38-3.35%
IN:SANOFICONRSanofi Consumer Healthcare India Limited3525.95-1095.86-23.71%
IN:ZOTAZota Health Care Ltd.1290.60-356.56-21.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 29, 2026